Polyrizon (Nasdaq: PLRZ) moves ahead on European nasal drug patent

Rhea-AI Filing Summary

Polyrizon Ltd. announced that the European Patent Office has completed technical preparations for publication of its European patent application EP 4751737 for mucoadhesive polymers used in nasal drug delivery. The application covers the company’s proprietary Trap & Target™ technology platform, designed to improve retention and absorption of drugs in the nasal cavity.

The publication is described as an important step in Polyrizon’s strategy to build its intellectual property portfolio and support future pharmaceutical collaborations in nasal drug delivery. The patent application remains under European examination, and any eventual grant could offer protection in multiple European markets but is not assured.

Key Figures

Patent publication number: EP 4751737 Press release date: June 10, 2026 Most recent Form 20-F year: Year ended December 31, 2025

3 metrics

Patent publication number EP 4751737 European nasal drug delivery patent application

Press release date June 10, 2026 Announcement of European patent publication preparations

Most recent Form 20-F year Year ended December 31, 2025 Risk factors reference for forward-looking statements

Key Terms

mucoadhesive polymer technology, nasal drug delivery, intellectual property portfolio, European Patent Office (EPO), +2 more

6 terms

mucoadhesive polymer technology technical

"The patent application covers Polyrizon’s proprietary Trap & Target™ (T&T) mucoadhesive polymer technology platform for nasal drug delivery."

nasal drug delivery medical

"Nasal drug delivery has emerged as an increasingly attractive administration route for a wide range of therapeutic compounds."

Nasal drug delivery is a way to give medicines through the nose, using sprays, drops or inhaled powders so the drug is absorbed through the nasal lining instead of swallowed or injected. It matters to investors because this route can produce faster effects, better patient convenience and lower development or marketing hurdles for some products, potentially increasing a drug’s commercial appeal and competitive edge — think of it like delivering a package straight to the front door rather than routing it through a warehouse.

intellectual property portfolio financial

"The publication of the patent application represents a significant milestone in the Company's strategy to strengthen its intellectual property portfolio."

A collection of a company’s legally recognized creations and rights—such as patents, trademarks, copyrights, trade secrets and licensing agreements—that together protect its products, brands and technologies. Think of it as the company’s toolbox or recipe box: some items keep competitors out, some can be rented or sold, and some enable unique products. For investors, the breadth and strength of this portfolio affect future revenue potential, competitive position and legal risk, so it influences valuation and investment decisions.

European Patent Office (EPO) regulatory

"the European Patent Office (EPO) has completed the technical preparations for the publication of the Company's European patent application."

A regional patent authority that examines and grants patents for inventions across multiple European countries, the European Patent Office (EPO) decides whether new products, processes or technologies meet legal standards for protection. Investors care because EPO grants can create exclusive market rights like a ’temporary monopoly,’ helping a company protect revenue, justify higher valuations, and reduce competition risk—similar to locking a valuable invention behind a gate.

forward-looking statements regulatory

"This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws."

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

pre-clinical development medical

"its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of June 2026

Commission file number: 001-42375

Polyrizon Ltd.

(Translation of registrant’s name into English)

8 Ha-Pnina Street

Raanana, 4321545, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the Registrant’s press release issued on June 10, 2026, titled “Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology.”

The first, second, third and fifth paragraphs of the press release attached to this Report of Foreign Private Issuer on Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements on Form S-8 (File No. 333-284410 and 333-288923) and Form F-3 (333-291368), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology”

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Polyrizon Ltd.
Date: June 10, 2026	By:	/s/ Tomer Izraeli
	Name:	Tomer Izraeli
	Title:	Chief Executive Officer

2

 Exhibit 99.1

Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology

Raanana, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced that the European Patent Office (EPO) has completed the technical preparations for the publication of the Company's European patent application entitled “Mucoadhesive Polymers for Nasal Drug Delivery.” The application was published under European publication number EP 4751737. The patent application covers Polyrizon’s proprietary Trap & Target™ (T&T) mucoadhesive polymer technology platform for nasal drug delivery. The technology is designed to enhance the interaction between pharmaceutical formulations and the nasal mucosa, potentially increasing formulation retention, improving drug absorption, and enabling more efficient delivery of active pharmaceutical ingredients through the nasal route.

Nasal drug delivery has emerged as an increasingly attractive administration route for a wide range of therapeutic compounds, offering rapid onset of action, non-invasive administration, and the potential to bypass gastrointestinal degradation and first-pass metabolism. Polyrizon’s technology is intended to address one of the key challenges of nasal administration, limited residence time within the nasal cavity, through the development of advanced mucoadhesive polymer systems.

The publication of the patent application represents a significant milestone in the Company's strategy to strengthen its intellectual property portfolio supporting future pharmaceutical applications and collaborations in the nasal drug delivery field.

"The forthcoming publication of this European patent application marks an important step in strengthening our position in the growing nasal drug delivery market," said Tomer Izraeli, Chief Executive Officer of Polyrizon. "We believe our proprietary mucoadhesive polymer technology has the potential to improve the performance of nasal drug delivery systems across a broad range of therapeutic applications. Expanding our patent portfolio remains a key component of our strategy as we continue to advance innovative solutions for pharmaceutical partners and future product opportunities."

The patent application will continue through the European examination process. If granted, the patent could provide intellectual property protection across multiple European markets, further supporting Polyrizon’s potential commercialization and partnering efforts in the pharmaceutical sector.

About Polyrizon

Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain ^TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target, or T&T. For more information, please visit https://polyrizon-biotech.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the Company's strategy to strengthen its intellectual property portfolio supporting future pharmaceutical applications and collaborations in the nasal drug delivery field, strengthening its position in the growing nasal drug delivery market, the expected growth of the nasal drug delivery market, advancing innovative solutions for pharmaceutical partners and future product opportunities and its potential commercialization and partnering efforts in the pharmaceutical sector. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. .  Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.

Contacts:

Michal Efraty
Investor Relations
IR@polyrizon-biotech.com

FAQ

What did Polyrizon (PLRZ) announce in its latest 6-K filing?

Polyrizon announced that the European Patent Office completed technical preparations to publish its European patent application EP 4751737. The application covers its Trap & Target mucoadhesive nasal drug delivery technology, a key part of the company’s intellectual property strategy in nasal drug delivery.

What technology is covered by Polyrizon’s European patent application EP 4751737?

The patent application covers Polyrizon’s Trap & Target mucoadhesive polymer technology platform for nasal drug delivery. This technology is designed to enhance interaction with nasal mucosa, potentially increasing formulation retention, improving drug absorption, and enabling more efficient nasal delivery of active pharmaceutical ingredients.

Why is nasal drug delivery important to Polyrizon (PLRZ)?

Polyrizon focuses on nasal drug delivery because it can offer rapid onset, non-invasive administration, and avoidance of gastrointestinal degradation and first-pass metabolism. Its mucoadhesive technologies aim to address limited residence time in the nasal cavity, a key challenge for effective intranasal therapies.

How does Polyrizon describe the significance of its European patent publication step?

Polyrizon describes the forthcoming publication as a significant milestone in strengthening its intellectual property portfolio. The company believes this step supports future pharmaceutical applications, collaborations, and potential commercialization efforts in the growing nasal drug delivery market, subject to the outcome of the European examination process.

What stage of development is Polyrizon’s Trap & Target (T&T) technology in?

Polyrizon states that Trap & Target technology for nasal delivery of active pharmaceutical ingredients is in an earlier stage of pre-clinical development. It sits alongside the company’s Capture and Contain hydrogel technology, which focuses on creating a nasal barrier against viruses and allergens.

Does Polyrizon’s filing guarantee that a European patent will be granted?

No, Polyrizon explicitly notes it cannot assure that any patent will issue from the pending application, or that any granted patent will be advantageous. The application will continue through the European examination process, and outcomes may differ from current expectations described in forward-looking statements.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE TITLED: "POLYRIZON RECEIVES NOTICE OF EUROPEAN PATENT PUBLICATION 10.0 KB